ArticleTranslational lung cancer research2025
Lobectomy plus lobe-specific lymphadenectomy as the minimum standards of curative resection for hypermetabolic clinical stage IA non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lobectomy, segmentectomy, and wedge resection for elderly patients with solid-predominant stage I NSCLC: survival, pulmonary function, and postoperative outcomes.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The results of three modern randomized controlled trials have proved sublobar resection as an effective procedure for early-stage non-small cell lung cancer (NSCLC) up to 2 cm. We aimed to examine whether sublobar resection is oncologically feasible and what constitutes adequate lymph node assessment for hypermetabolic clinical stage IA (cIA) NSCLC. Methods: A single-center retrospective study was conducted in 589 patients who underwent lobectomy (n=526) or sublobar resection (n=63) for hypermetabolic cIA NSCLC [maximum standardized uptake value (SUVmax) ≥2.6 g/dL]. The primary outcomes (lung cancer-specific death and tumor recurrence) were compared in a competing risks framework for all patients and the propensity score matched pairs. Random forests were used to examine the variable importance for lung cancer-specific survival and tumor recurrence. Factors affecting pathological upstaging and recurrence-free survival were assessed by logistic regression analysis and Cox regression analysis, respectively. Results: Sublobar resection had significantly higher lung cancer-specific cumulative incidence of death (LC-CID) and cumulative incidence of recurrence (CIR) than lobectomy after matching (5-year LC-CID, 20.8% Conclusions: Lobectomy was oncologically superior to sublobar resection as a curative-intent procedure for hypermetabolic cIA NSCLC. Lobectomy plus lobe-specific lymphadenectomy should be considered as the minimum standards of curative resection for hypermetabolic early-stage NSCLC in order to achieve more accurate pathological N staging and better cancer control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.